354 related articles for article (PubMed ID: 17172842)
41. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
42. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
43. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
[TBL] [Abstract][Full Text] [Related]
44. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
[TBL] [Abstract][Full Text] [Related]
45. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
46. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
47. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
de Alava E; Panizo A; Antonescu CR; Huvos AG; Pardo-Mindán FJ; Barr FG; Ladanyi M
Am J Pathol; 2000 Mar; 156(3):849-55. PubMed ID: 10702401
[TBL] [Abstract][Full Text] [Related]
48. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
Erkizan HV; Uversky VN; Toretsky JA
Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
50. Identification of a Novel
Boone MA; Taslim C; Crow JC; Selich-Anderson J; Watson M; Heppner P; Hamill J; Wood AC; Lessnick SL; Winstanley M
Mol Cancer Res; 2021 Nov; 19(11):1795-1801. PubMed ID: 34465585
[TBL] [Abstract][Full Text] [Related]
51. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.
Sorensen PH; Lessnick SL; Lopez-Terrada D; Liu XF; Triche TJ; Denny CT
Nat Genet; 1994 Feb; 6(2):146-51. PubMed ID: 8162068
[TBL] [Abstract][Full Text] [Related]
52. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
53. Transformation induced by Ewing's sarcoma associated EWS/FLI-1 is suppressed by KRAB/FLI-1.
Chan D; Wilson TJ; Xu D; Cowdery HE; Sanij E; Hertzog PJ; Kola I
Br J Cancer; 2003 Jan; 88(1):137-45. PubMed ID: 12556973
[TBL] [Abstract][Full Text] [Related]
54. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
55. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
[TBL] [Abstract][Full Text] [Related]
56. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma.
Fuchs B; Inwards CY; Janknecht R
Clin Cancer Res; 2004 Feb; 10(4):1344-53. PubMed ID: 14977835
[TBL] [Abstract][Full Text] [Related]
58. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.
Ouchida M; Ohno T; Fujimura Y; Rao VN; Reddy ES
Oncogene; 1995 Sep; 11(6):1049-54. PubMed ID: 7566963
[TBL] [Abstract][Full Text] [Related]
59. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
Jeon IS; Davis JN; Braun BS; Sublett JE; Roussel MF; Denny CT; Shapiro DN
Oncogene; 1995 Mar; 10(6):1229-34. PubMed ID: 7700648
[TBL] [Abstract][Full Text] [Related]
60. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors.
Potikyan G; France KA; Carlson MR; Dong J; Nelson SF; Denny CT
Lab Invest; 2008 Dec; 88(12):1291-302. PubMed ID: 18838963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
